Stocks / Dr Reddy's Laboratories (DRREDDY)

DRREDDY Share Price, Analysis & News

Dr Reddy's Laboratories (DRREDDY) — Updated on 2026-05-08

Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company operating within the biotechnology & drugs industry. The company's business model focuses on its operations as a pharmaceutical entity. Investors closely monitor the Dr Reddy's Laboratories share price to understand its market performance and potential returns. Analysis of the Dr Reddy's Laboratories business model, alongside sector trends and company fundamentals, provides insights into its financial health and future prospects. Understanding these elements is key for evaluating the stock within the broader biotechnology and drug market.
Overview Daily Weekly

Key Takeaway

Despite recent declines and mixed analyst sentiment, Dr Reddy's shows a bullish technical trend with RSI at 52.57, though profitability declined YoY.

Daily

2026-05-08
  • The stock is exhibiting a bullish trend, trading above key moving averages (9, 21, 50-day EMAs) with a positive trend alignment score of 3, indicating a favorable technical setup for sustained upward movement.
  • Momentum appears neutral to bullish, supported by an RSI of 52.57 and a MACD signal that suggests potential for further price appreciation, though it's not yet in overbought territory.
  • While short-term returns have dipped by -2.19% over the last week and 5 days, the stock posted a stronger 1-month return of 8.18%, suggesting resilience and a possible recovery from recent minor pullbacks.
  • Fundamentally, the company's revenue for the Dec 2025 quarter was ₹8,753 Cr, but net profit and EPS declined QoQ and YoY, indicating some pressure on profitability.
  • Analysts maintain a mixed outlook with a slight lean towards bearish sentiment, as 42.11% recommend Sell or Strong Sell, though this distribution has been stable over the past month.
  • Institutional investors, including FIIs and DIIs, collectively hold a significant 51.86% stake, though there has been a notable decrease in FII holdings and a corresponding increase in public shareholding this quarter.
Open daily analysis

Weekly

Latest weekly signal
  • The stock price declined by 2.19 percent this week, accompanied by a 19.19 percent drop in trading volume, indicating reduced market participation.
  • Technical momentum shows a cooling effect as the Relative Strength Index (RSI, a measure of price speed) moved toward a neutral stance at 52.57.
  • The company clarified that Health Canada approval for its Semaglutide Injection remains pending, despite earlier reports of a received notice.
  • Financial performance for the quarter ending December 2025 showed a divergence, with revenue growing 4.4 percent while net profit declined by 15.2 percent.
  • Market sentiment shifted during the week, transitioning from a downgrade on May 5 to signs of renewed technical strength by May 7.
Open weekly analysis

Quarterly

Latest quarterly update
Detailed analysis available on the full page.

Price & Technical Structure

  • Short-term returns show a decline over the last 1 week (-2.19%) and 5 days (-2.19%), despite a positive 1-month return of 8.18%.
  • The trend regime is bullish, with the price trading above the 9, 21, and 50-day EMAs, and a positive trend alignment score of 3.
  • Momentum is neutral to bullish, indicated by an RSI of 52.57 and a bullish MACD signal.
  • Volatility is moderate, with the price positioned at 59.74% of the Bollinger Band width, suggesting room for price movement.
  • Structural positioning shows the price is 5.11% below its 52-week high and has experienced a current drawdown of -5.11%.
The market is exhibiting a bullish trend supported by EMAs and a positive trend alignment score. Momentum indicators like RSI and MACD suggest a neutral to bullish stance. Volatility remains moderate, with the price trading within the Bollinger Bands. Structurally, the asset is trading below its 52-week high, with a minor current drawdown. Short-term returns have seen a dip, contrasting with positive monthly performance.

Weekly Momentum

  • The stock price declined by 2.19 percent this week, accompanied by a 19.19 percent drop in trading volume, indicating reduced market participation.
  • Technical momentum shows a cooling effect as the Relative Strength Index (RSI, a measure of price speed) moved toward a neutral stance at 52.57.
  • The company clarified that Health Canada approval for its Semaglutide Injection remains pending, despite earlier reports of a received notice.
  • Financial performance for the quarter ending December 2025 showed a divergence, with revenue growing 4.4 percent while net profit declined by 15.2 percent.
  • Market sentiment shifted during the week, transitioning from a downgrade on May 5 to signs of renewed technical strength by May 7.
Dr. Reddy's Laboratories experienced a week of price consolidation and mixed sentiment. While the stock remains above its 50-day and 200-day moving averages, the weekly decline and lower trading volume suggest a period of reduced conviction among market participants. The company's clarification regarding regulatory status for its Semaglutide injection and the upcoming earnings announcement on May 12 have contributed to a volatile news cycle. Financial results from the previous quarter highlight a challenging environment where revenue growth is currently offset by a contraction in net profitability. The technical regime remains trend-dominant, though momentum indicators are cooling as volatility contracts.